Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper

Karelle Ménocheta Quantitative Discovery and Development, UCB, Slough, UKCorrespondence[email protected]
View further author information

Hongbin Yub R&D Project Management and Development Strategies, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USAView further author information

Bonnie Wangc Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Inc, Princeton, NJ, USAView further author information

Jay Tibbittsd Nonclinical Development, South San Francisco, CA, USAView further author information

Cheng-Pang Hsue Preclinical Development and Clinical Pharmacology, AskGene Pharma Inc, Camarillo, CA, USAView further author information

Amrita V. Kamathf Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USAView further author information

Wolfgang F. Richterg Roche Pharma Research and Early Development, Roche Innovation, Center Basel, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information

Andreas Baumannh R&D, Bayer Pharma AG, Berlin, Germany & Non-clinical Biotech Consulting, Potsdam, Germany °(° present affiliation)View further author information

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.